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Abstract: COPD is a chronic disease and, like many other chronic diseases, there is no treatment 
to reverse the severity of the disease except for lung transplant. To date, no inhaled medications 
have been shown to improve survival. Tiotropium bromide is a long-acting inhaled anticholinergic 
drug for the treatment of COPD that can improve lung function, reduce symptoms and exacerba-
tions, and improve quality of life with once-daily dosing. It was initially approved and marketed 
in several countries in Europe in 2002 and then approved in the US in 2004. Tiotropium is gener-
ally well tolerated with dry mouth being the main adverse effect. Other adverse effects include 
constipation, tachycardia, blurred vision, urinary retention and increased intraocular pressure. 
Despite the recently raised concerns about an excess risk of cardiovascular adverse events with 
inhaled anticholinergic agents, the risk/beneﬁ  t ratio of tiotropium appears still favorable given the 
favorable safety proﬁ  le demonstrated in the UPLIFT study. However, caution should be advised 
in patients at high risk for cardiovascular disease given the paucity of data in such patients.
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Management issues in treating COPD
COPD is a chronic disease and, like many other chronic diseases, there is no treatment 
to reverse the severity of the disease except for lung transplant. COPD is the fourth leading 
cause of death in the US and is expected to be the third by 2020. The prevalence of COPD 
is on the increase globally with an attendant increase in morbidity and mortality.
Despite the recent advances in understanding of the disease and its management, 
only a few therapies can have an impact on mortality in patients with stable COPD. 
These therapies include smoking cessation (Anthonisen et al 2005), continuous oxygen 
therapy for hypoxemic patients (Nocturnal Oxygen Therapy Trial Group 1980; Medical 
Research Council Working Party 1981), inﬂ  uenza vaccination (Nichol et al 1999), and 
lung reduction surgery for selected patients (Fishman et al 2003).
Pharmacotherapy for COPD has been used to alleviate symptoms, prevent exacerba-
tions, and improve exercise capacity and quality of life. However, to date no inhaled 
medications have been shown to improve survival. The international guidelines devel-
oped by Global Initiative for Chronic Obstructive Lung Disease currently set the standard 
of care (Rabe et al 2007) and long-acting bronchodilators are considered as the ﬁ  rst-line 
maintenance therapy in patients with moderate to severe COPD.
The US Food and Drug Administration (FDA) recently issued a black box warning to 
long-acting beta agonists (LABAs) for asthma to alert healthcare professionals and patients 
that these medicines may increase the chance of severe asthma episodes and death (FDA 
2005). Although information is not available for similar concerns applicable to patients with 
COPD, caution may be advised given the relatively high prevalence of reversible component 
in patients with very severe COPD and exclusion of such patients in most clinical trials.
A recent observational study of a cohort of 175,906 elderly COPD patients found 
that the use of inhaled corticosteroids (ICSs) was associated with a dose-dependent International Journal of COPD 2008:3(4) 576
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increase in hospitalization with pneumonia followed by death 
within 30 days (Ernst et al 2007).
Combination therapy with a LABA with an ICS reduces 
COPD-related hospitalizations in patients with moderate 
to severe COPD and is the only pharmacotherapy that has 
been shown to alter the decline in lung function, which is a 
hallmark of the disease (Calverley et al 2007). Further studies 
are needed to determine whether this combination might 
increase the number of adverse side effects given recently 
raised concerns with LABAs and ICSs.
Tiotropium bromide (Boehringer Ingelheim, Ingelheim, 
Germany) is a long-acting inhaled anticholinergic agent 
for the treatment of COPD that can improve lung function, 
reduce symptoms and COPD-related hospitalizations, and 
improve quality of life with once-daily dosing. The results 
of some studies have suggested that tiotropium is more 
effective than LABAs in reducing COPD-related hospital-
izations and improving quality of life (Brusasco et al 2003; 
Oba 2007). Tiotropium was initially approved and marketed 
in several countries in Europe in June 2002 and then in the 
US in early 2004.
Two recently published studies have raised concerns for a 
possible increase in mortality and cardiovascular events with 
the use of inhaled anticholinergics. In a nested case-control 
study of a cohort of 32,120 COPD patients and 320,501 con-
trol participants, ipratropium bromide (Boehringer Ingelheim, 
Ingelheim, Germany) was associated with an increased risk for 
mortality, whereas ICSs appeared to reduce the risk for death 
(Lee et al 2008). In a 17-trial meta-analysis, the use of inhaled 
anticholinergics (ipratropium and tiotropium) was associated 
with an increased risk for a composite of myocardial infarction 
(MI), stroke and cardiovascular death (Singh et al 2008).
Although recent guidelines have advocated the use of 
inhaled anticholinergics for disease control (Rabe et al 2007), 
there has been a growing concern in the clinical community 
that inhaled anticholinergics might increase the risk for 
cardiovascular events and mortality as describe above. This 
review examines the safety, tolerability and risk/beneﬁ  t ratio 
of a long-acting anticholinergic agent, tiotropium bromide.
Overview of pharmacology 
of tiotropium and short- 
and long-acting bronchodilators
Short- and long-acting bronchodilators
Short-acting beta-2 agonists act directly upon bronchial 
smooth muscle causing the airways to dilate for up to 6 hours. 
In turn, this improves ‘smooth muscle dependent’ outcome 
parameters such as symptoms and airway caliber (Sestini 
et al 2003).
The prime action of beta-adrenergic drugs is to stimulate 
adenyl cylase, the enzyme that catalyzes the formation 
of cyclic-3, 5-adenosine monophosphate from adenosine 
triphosphate.
Similar to short-acting agents, LABAs act directly upon 
beta-2 adrenoreceptors, causing smooth muscle to relax 
and airways to dilate. Both salmeterol (GlaxoSmithKline, 
Brentford, UK) and formoterol (Foradil®, Novartis Pharma 
AG, Basel, Switzerland) are relatively lipophilic, which may 
in part explain their prolonged duration of action.
Salmeterol interacts with both the active site and an exosite 
of the beta-2 adrenoreceptor, and the molecular basis of this 
interaction is termed the salmeterol hinge (charniere) theory 
(Pauwels et al 2001; Celli and MacNee 2004). Formoterol is 
partially lipophilic and forms a membrane depot. Formoterol 
has a more rapid onset of action than salmeterol (National 
Collaborating Centre for Chronic Conditions 2004).
The onset of action for both short- and long-acting 
beta-2 agonist is 5 to 15 min. Effects of short-acting agents 
usually last only 4 to 6 hours whereas those of LABAs last 
12 hours.
Short- and long-acting anticholinergics
The characteristic airﬂ  ow obstruction in COPD is multi-
factorial in origin and in part due to potentially reversible 
high cholinergic tone (Gross and Skorodin 1984; Chapman 
et al 1990). Moreover, vagally mediated mechanisms are 
also implicated in enhanced submucosal gland secretion in 
patients with COPD (Dahl et al 2001).
Short-acting anticholinergics such as ipratropium (with a 
duration of action of 3 to 6 hours) offset high resting bron-
chomotor tone to relax smooth muscle with subsequent 
improvement in airway caliber (Mahler et al 1999; Dahl et al 
2001; Rennard et al 2001).
Three main subtypes (M1, M2 and M3) of muscarinic 
receptors exist. The activation of both M1 and M3 receptors 
results in bronchoconstriction whereas the M2 receptor is 
protective against such an effect.
In contrast to ipratropium, tiotropium dissociates rapidly 
from the M2 receptor (therefore minimizing the loss of any 
putative beneﬁ  t) and dissociates only slowly from the M3 
receptor (Disse et al 1993). This in turn causes a reduction 
in resting bronchomotor tone, smooth muscle to relax and 
airways to dilate for a greater length of time. The prolonged 
duration of action of tiotropium therefore facilitates once-
daily administration with potential concordance beneﬁ  ts.International Journal of COPD 2008:3(4) 577
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The peak onset of bronchodilation with tiotropium occurs 
between 1 to 3 hours with improvements in FEV1 persisting 
for over 24 hours (Barnes et al 2000). In a pharmacodynamic 
study, it was discovered that 90% of the improvement in 
FEV1 was achieved within 24 hours of ﬁ  rst inhalation of 
tiotropium, while ongoing improvements in forced vital 
capacity were expected beyond 1 week of regular treatment 
(van Noord et al 2002).
Tolerability
Inhaled LABAs are generally well tolerated although adverse 
effects such as ﬁ  ne tremor and palpitations are occasionally 
troublesome. These agents should be used in caution in 
patients with cardiovascular disease, at risk of developing 
prolongation of the QT interval and in whom concomitant 
drug administration may increase the risk of serious hypo-
kalaemia (Salpeter et al 2004).
Tiotropium is generally well tolerated and poorly 
absorbed from the gastrointestinal tract, but as with all 
inhaled anti-cholinergic agents, care should be taken in 
patients with glaucoma and prostatic hyperplasia. In clinical 
trials comparing tiotropium with placebo, the frequency of 
dry mouth, constipation, and urinary tract infection appears 
to increase with patient age. Further details are described in 
the following section.
It is also important to point out that no tachyphylaxis to 
its bronchodilatory effect has been observed with tiotropium 
(Casaburi et al 2000), a phenomenon that is known to occur 
with LABAs (Donohue et al 2003).
Safety and tolerability of tiotropium
Comparison with placebo
Tiotropium was generally well tolerated in randomized clini-
cal trials which ranged from 2 to 12 months (Casaburi et al 
2002; Brusasco et al 2003; Niewoehner et al 2005; Dusser 
et al 2006; Verkindre et al 2006; Chan et al 2007; Criner et al 
2008). In all studies, the completion rate was higher with 
tiotropium (77%–98%) than with placebo (71%–92%). The 
most commonly cited reason for withdrawal was worsening 
of COPD or adverse events. The completion rate in a recently 
published 4-year randomized controlled trial involving 
5993 patients (UPLIFT, Understanding Potential Long-Term 
Impacts on Function with Tiotropium; Tashkin et al 2008) 
was signiﬁ  cantly higher with tiotropium than with placebo 
(63% vs 55%, p  0.0001). The most common reason for 
withdrawal in the UPLIFT study was adverse events.
We conducted a pooled analysis to examine the incidence 
of serious adverse events (SAEs) and all-cause mortality 
using the same methods as in a recent meta-analysis by Singh 
et al. Ten randomized control trials reported incidence of 
SAEs (Casaburi et al 2000, 2002, 2005; Covelli et al 2005; 
Niewoehner et al 2005; Chan et al 2007; Criner et al 2008; 
Moita et al 2008; Tashkin et al 2008; Voshaar et al 2008) 
and 11 trials reported all-cause mortality (Casaburi et al 
2000, 2002, 2003, 2005; Niewoehner et al 2005; Chan 
et al 2007; Powrie et al 2007; Criner et al 2008; Moita et al 
2008; Tashkin et al 2008; Voshaar et al 2008). There was 
no difference in all-cause mortality between the tiotro-
pium and placebo recipients when all reported results were 
combined (odds ratio [OR] 0.94; 95% conﬁ  dence interval 
[CI] 0.82–1.08). However, the incidence of SAEs was 
signiﬁ  cantly lower in the tiotropium recipients (OR 0.88; 
95% CI 0.81–0.96). (Figure 1) The most frequently reported 
SAEs were respiratory events such as COPD exacerbation 
or pneumonia (Casaburi et al 2005; Covelli et al 2005; 
Niewoehner et al 2005; Criner et al 2008; Tashkin et al 2008). 
The incidence of discontinuation due to adverse events was 
signiﬁ  cantly lower with tiotropium than with placebo (21% 
vs 25%, p  0.0001) in the UPLIFT study (Tashkin et al 
2008) as well as in a pooled analysis conducted by us (OR 
0.79; 95% CI 0.71–0.88) (Figure 2).
The causes of death were consistent with what might 
be expected in the patient population. In a meta-analysis, 
pulmonary mortality was non-significantly lower with 
tiotropium than with placebo (OR 0.5; 95% CI 0.19–1.29) 
(Barr et al 2006). Cardiovascular (OR 1.17; 95% CI 0.54–2.51) 
and cancer mortality (OR 0.77; 95% CI 0.28–2.12) were simi-
lar in the tiotropium and placebo recipients.
There has been a growing concern in the clinical com-
munity that inhaled anticholinergics might increase the risk 
for cardiovascular adverse events. Although tiotropium 
was approved by FDA in 2004, the Pulmonary and Allergy 
Drugs Advisory Committee of the agency concerned about 
suggestions of increased cardiovascular risk when pivotal 
clinical trials were reviewed (FDA 2002). Barr et al (2006) 
conducted a meta-analysis in 2006 in which the frequency 
of arrhythmia was signiﬁ  cantly higher with tiotropium than 
with placebo when adjusted for statistical heterogeneity 
(OR 2.33; 95% CI 1.11–4.88).
In March 2008, The FDA issued a warning about a 
potential increased risk of stroke in patients using tiotropium 
(FDA 2008). Boehringer Ingelheim, the manufacturer of 
tiotropium, reported to the agency a preliminary estimate 
that the risk of stroke during 29 clinical trials was 8 patients 
per 1000 patients treated for 1 year with tiotropium and 
6 patients per 1000 patients treated with placebo for the same International Journal of COPD 2008:3(4) 578
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Figure 1 Summary effects of tiotropium on serious adverse events and all-cause mortality.
Abbreviations: CI, conﬁ  dence interval; OR, odds ratio.
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Figure 2 Forest plot examining the incidence of discontinuation due to adverse events with tiotropium vs placebo including the UPLIFT study.
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amount of time. In these trials, which included approximately 
13,500 patients with COPD, the estimated excess risk of any 
type of stroke caused by tiotropium was 2 patients for each 
1000 patients using tiotropium for 1 year. The FDA cautioned 
practitioners that the ﬁ  ndings were only preliminary and no 
regulatory action had been taken at that time.
After the FDA warning, two major studies were pub-
lished concerning the possible association between inhaled 
anticholinergics and elevated risk for all-cause mortality 
and cardiovascular events. One study, which was a nested 
case-control study with a cohort of 32,120 case patients and 
320,501 control participants, showed that ipratropium was 
associated with an increased risk for mortality in patients with 
COPD, whereas inhaled corticosteroids appeared to reduce 
the risk for death (Lee et al 2008). The use of ipratropium 
was associated with a higher risk of all-cause mortality 
(OR 1.11; 95% CI 1.08–1.15) and a 34 % increase (95% CI 
22%–47%) in the risk for cardiovascular death, whereas 
ICSs and LABAs both reduced the risk for all-cause mortal-
ity by 20% and 8%. ICSs were also associated with a 20% 
decrease (95% CI 12%–28%) in the risk for cardiovascular 
death (Lee et al 2008).
The other study was a 17-trial meta-analysis, in which the 
use of inhaled anticholinergics (ipratropium and tiotropium), 
compared with control (placebo or comparator), was associ-
ated with an increased risk for a composite of MI, stroke and 
cardiovascular death (Singh et al 2008). The use of inhaled 
anticholinergics in patients with COPD was associated an 
increase risk for MI with a number needed to harm of 174 per 
year and an increased risk for cardiovascular death with a 
number needed to harm of 40 per year. The authors concluded 
that clinician should closely monitor patients with COPD 
who were receiving an inhaled anticholinergic agent.
Soon after the above two studies were published, the 
manufacturer reported the results of the UPLIFT study, 
which is a large 4-year, randomized, placebo-controlled, 
double-blind trial of tiotropium in patients with moderate 
to severe COPD conducted at 490 centers in 37 courtiers 
involving 5993 patients (Tashkin et al 2004). The UPLIFT 
study provided additional long-term safety data and addi-
tional insight into the risk of stroke or other safety ﬁ  ndings 
of tiotropium.
Tiotropium showed a trend toward reduced mortality 
(14.9% vs 16.5%, hazard ratio [HR] 0.89; 95% CI 0.79–1.02 ). 
The incidence of adverse events (92.6% vs 92.3%) and the 
proportion of SAEs (51.6% vs 50.2%) were similar in the 
tiotropium and placebo group. Cardiovascular adverse events 
were signiﬁ  cantly less with tiotropium (relative risk [RR] 
0.84; 95% CI 0.73–0.98). The incidence of MI was also less 
with tiotropium (RR 0.71; 95% CI 0.52–0.99). There were 
82 strokes among the 2987 patients (2.7%) taking tiotro-
pium and 80 strokes among the 3006 patients (2.7%) taking 
placebo. The difference was not statistically signiﬁ  cant.
We reanalyzed the meta-analysis conducted by Singh 
et al (2008) incorporating the results of UPLIFT study 
to further investigate the possible association between 
tiotropium and increased risk of cardiovascular events. The 
association between inhaled anticholinergics (ipratropium 
and tiotropium) and increased risk for a composite of MI, 
stroke and cardiovascular death became no longer signiﬁ  cant 
with the use of tiotropium (Figures 3a, b).
We also found the following errors in the meta-analysis by 
Singh et al (2008): 1) The number of the control group in the 
study by Chan et al was 305 instead of 350 (Chan et al 2007). 
2) The incidence of serious cardiovascular events in the 
study by Wedzicha et al was 34 with tiotropium and 23 with 
placebo instead of 23 and 13 (Wedzicha et al 2008). 3) The 
study by Donohue et al (2002) should have been excluded 
since Brusasco et al (2003) reported combined results of 
the study by Donohue et al and another unpublished study 
(Barr 2004). Although these errors did not affect the results, 
they were corrected in our pooled analysis.
The difference in the cardiovascular events in the Singh’s 
study was primarily derived from long-term studies (ie, duration 
of study 6 months). We found evidence of possible publica-
tion bias when the long-term studies were analyzed with a 
funnel plot (Figure 4) and a statistical test (Horbold-Egger: 
bias = 0.722318 [92.5% CI = 0.450252–0.994383] p = 0.003). 
The difference in the cardiovascular events detected in the 
Singh’s study could be due to publication bias. The FDA is 
currenlty reconsidering its recent warning that tiotropium 
might raise stroke risk as of October 10, 2008. The FDA said 
it would take several months for it to ﬁ  nish its review of the 
huge amount of data from the UPLIFT study.
The adverse event data indicated that anticholinergic 
effects were more frequent with tiotropium (FDA 2002; 
Barr et al 2006). Dry mouth was by far the most common 
with an incidence of 16% with tiotropium and 2.7% with 
placebo (Casaburi et al 2002) and more frequent in women 
and older patients (FDA 2002). The peak incidence has been 
reported to occur after 3 to 4 weeks of therapy, when steady-
state concentrations are reached. Dry mouth was generally 
mild and resolved during treatment in most patients and less 
than 1% of the patients withdrew from the clinical studies 
as a result (Casaburi et al 2002, 2003; Vincken et al 2002). 
Other anticholinergic effects included constipation and International Journal of COPD 2008:3(4) 580
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Figure 3b Forest plot examining the incidence of composite cardiovascular events with anticholinergics vs control. Long-term trials (6 months) including UPLIFT study.
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urinary effects. The relative risk of urinary retention was 
signiﬁ  cantly increased in a pooled analysis (RR 10.9; 95% 
CI 1.26–94.9) (Kesten et al 2006). Upper respiratory tract 
infections were also more common with tiotropium than with 
placebo (41.1% vs 37.2%) (FDA 2002). The observation that 
dry mouth, constipation, and urinary tract infection occur 
more frequently with older age suggests that these adverse 
events represent systemic effects of the drug (FDA 2002). 
Tiotropium is associated with detectable plasma concentra-
tions, particularly with chronic use. Other factors that can 
increase systemic exposure are impaired renal function, 
increasing age, concomitant cimetidine, and cytochrome 
P450 2D6 poor metabolizers (FDA 2002). It should be noted 
that patients with urinary problems and glaucoma were 
excluded in the most clinical trials; therefore, anticholinergic 
side effects may be more common in a real-world setting. The 
adverse effects of tiotropium are summarized in Table 1.
Comparison with other bronchodilators
The tolerability of tiotropium in comparison with ipratro-
pium (Vincken et al 2002), salmeterol (Brusasco et al 2003; 
Briggs et al 2005), formoterol (van Noord et al 2005), or 
salmeterol/ﬂ  uticasone (SFC) combination (Bateman et al 
2008; Wedzicha et al 2008) was investigated in randomized 
clinical trials.
Fewer patients treated with tiotropium than with 
ipratropium (15.2% vs 21.2%) withdrew from the 1-year 
study (Vincken et al 2002) but the difference was not 
statistically signiﬁ  cant (p = 0.08). The withdrawal rates 
were also lower with tiotropium than with salmeterol. The 
difference was statistically signiﬁ  cant in the 6-month trial 
(15.4% vs 18.8%; p  0.05) (Brusasco et al 2003) but not 
in the 3-month trial (Briggs et al 2005) (8.8% vs 12.6%; 
p = 0.15). Similar proportions of tiotropium and formoterol 
recipients withdrew from the randomized crossover study 
(van Noord et al 2005).
The withdrawal rate was similar between tiotropium and 
SFC in a 6-week trial (Bateman et al 2008. However, in a 
2-year randomized control trial, the withdrawal rate was 
signiﬁ  cantly higher with tiotropium compared with SFC (HR 
1.29; 95% CI 1.08–1.54; p = 0.005) (Wedzicha et al 2008). 
In this study, more patients treated with tiotropium withdrew 
from the study because of COPD exacerbation, perceived 
lack of efﬁ  cacy, or unwillingness to remain in the study.
There was no statistically signiﬁ  cant difference in all-
cause mortality comparing tiotropium with ipratropium 
(Vincken et al 2002) or salmeterol (Brusasco et al 2003; 
Kesten et al 2006). However, mortality was signiﬁ  cantly 
higher with tiotropium than with SFC (6% vs 3%; p = 0.032) 
(Wedzicha et al 2008). The leading causes of death, in order 
of prevalence, were cardiac, respiratory and neoplastic dis-
orders. The incidence of cardiac death was non-signiﬁ  cantly 
higher with tiotropium than with SFC (3% vs 1%; p = 0.09). 
The authors concluded that further studies powered on 
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Figure 4 Funnel plot inspection on major adverse cardiovascular events in the long-term trials reveals signiﬁ  cant asymmetry which suggests publication bias.
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mortality would be required to conﬁ  rm these ﬁ  ndings since 
the all-cause mortality was not a primary outcome in the 
study (Wedzicha et al 2008). It should be kept in mind that 
this study compared one drug (ie, tiotropium) with a com-
bination therapy with a LABA and an ICS (ie, salmeterol 
plus ﬂ  uticasone).
Dry mouth occurred more frequently with tiotropium 
than with ipratropium (12.1% vs 6.1%; p = 0.03) (Vincken 
et al 2002) or with salmeterol (8.2% vs 1.7%; p  0.05) 
(Brusasco et al 2003). According to a recent meta-analysis 
(Barr et al 2006), other anticholinergic adverse events such 
as constipation, urinary retention and urinary tract infec-
tions occurred more frequently with tiotropium than with 
ipratropium or salmeterol. However, the differences were 
not statistically signiﬁ  cant. The incidence of adverse cardiac 
events was similar between tiotropium and SFC (5% vs 3%, 
Wedzicha et al 2008) or salmeterol (Brusasco et al 2003; 
Singh et al 2008). However, it is unlikely that these studies 
were sufﬁ  ciently powered to detect a signiﬁ  cant difference 
in the incidence of cardiac adverse events.
Patient satisfaction, adherence, 
and quality of life
In clinical practice, frequent administration creates a problem 
with drug adherence. Adherence with inhaled medications are 
generally fair to poor with compliance rates of somewhere 
between 10% and 50% (Rand et al 1995; Breekveldt-Postma 
et al 2004; Bender et al 2006; Kingsman et al 2007). Once-a-
day administration with tiotropium is likely to improve com-
pliance compared to multiple daily administration required 
with other inhaled medications. In a retrospective analysis 
including 5330 patients in the Netherlands, about 37% of new 
users of tiotropium continued treatment for 1 year whereas 
only 14% with ipratropium, 13% with LABA and 17% with 
LABA plus ICS remained on the treatment for the same 
duration (Breekveldt-Postma et al 2007). A Canadian study 
also showed that patients taking tiotropium had signiﬁ  cantly 
longer persistence at 12 months compared with other inhaled 
medications including ipratropium, ipratropium plus salbu-
tamol, formoterol, formoterol plus budesonide, salmeterol, 
and salmeterol plus ﬂ  uticasone (53% vs 7% to 30%; all 
p  0.0001) (Cramer et al 2007).
There is a paucity of data on patient satisfaction with 
long-acting bronchodilators.
Risk beneﬁ  t analysis of tiotropium
Tiotropium can improve lung function, reduce symptoms and 
exacerbations, and improve quality of life with once-daily 
dosing (Barr et al 2006). Tiotropium also showed a trend 
toward reduced mortality and induced long-term improve-
ment in the UPLIFT study (Tashkin et al 2008).
Tiotropium is generally well tolerated with dry mouth 
being the main adverse effect.
Despite recently raised concerns about possible associa-
tion between inhaled anticholinergics and elevated cardiovas-
cular events, the risk/beneﬁ  t ratio of tiotropium still appears 
favorable in symptomatic patients with moderate-to-severe 
COPD given the favorable safety proﬁ  le demonstrated in 
the UPLIFT study. There were fewer cardiovascular events 
with tiotropium compared with placebo in the UPLIFT study. 
Our pooled analyses incorporating the UPLIFT study also 
conﬁ  rmed the cardiac safety of tiotropium (Figures 1, 3). 
Respiratory events including COPD-related exacerbations 
and hospitalizations were also signiﬁ  cantly less with tiotro-
pium (RR 0.84; 95% CI 0.77–0.92) as shown in previous 
studies (Barr et al 2006; Oba 2007).
One caveat is that cardiac safety database is very limited 
in high-risk patients such as those with coronary artery 
disease, heart failure, cardiac arrhythmia, hypoxemia requir-
ing daytime oxygen therapy, and a creatinine 2.0 mg/dL 
since such patients were excluded from phase III clinical 
trials (Vincken et al 2002; Brusasco et al 2003; Casaburi 
et al 2005; Niewoehner et al 2005; Dusser et al 2006; 
Table 1 Adverse effects of tiotropium
Severe reactions
 Hypersensitivity  reaction
 Angioedema
 Paradoxical  bronchospasm
  Increased intraocular pressure/glaucoma
 Paralytic  ileus
 Angina  pectoris
 Stroke
Common reactions (1%)
  Upper respiratory tract infection, pharyngitis, sinusitis
  Dry mouth, throat irritation
  Chest pain, tachycardia, palpitations
  Urinary tract infection, urinary hesitancy/retention
  Dyspepsia, vomiting, constipation, abdominal pain
 Edema
 Myalgia
 Epistaxis
 Rash
 Candidiasis
  Acute angle closure glaucoma, blurred vision, cataractInternational Journal of COPD 2008:3(4) 583
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Tashkin et al 2008). Those patients may be at increased risk 
of drug-related cardiac events in a real-world setting.
Currently, it is largely clinician and patient preferences as 
to which inhaled long-acting bronchodilator to be used as the 
ﬁ  rst-line maintenance therapy in symptomatic patients with 
moderate-to-severe COPD (Qaseem et al 2007; Rabe et al 
2007). For example, clinicians may prefer SFC over tiotro-
pium given possible mortality beneﬁ  t and/or better tolerabil-
ity with SFC (Calverley et al 2007; Wedzicha et al 2008). 
Clinicians and patients may elect to use tiotropium over 
salmeterol if patients are experiencing frequent exacerbations 
or hospitalizations (Barr et al 2006). Third-party payers may 
elect tiotropium over salmeterol as a preferred drug in their 
formulary given more favorable cost-effectiveness ratio with 
tiotropium (Oba 2007).
Conclusions
Tiotropium bromide is a long-acting inhaled anticholinergic 
agent and one of the ﬁ  rst-line maintenance therapies in symp-
tomatic patients with moderate-to-severe COPD. Tiotropium 
is generally well tolerated with dry mouth being the main 
adverse effect, which is generally not troublesome enough 
to discontinue the drug. Other adverse effects include con-
stipation, tachycardia, blurred vision, urinary retention and 
increased intraocular pressure. Despite the recently raised 
concerns about an excess risk of cardiovascular adverse 
events with inhaled anticholinergic agents, the risk/beneﬁ  t 
ratio of tiotropium appears still favorable given the favor-
able safety profile demonstrated in the UPLIFT study. 
However, caution should be advised in patients at high risk 
for cardiovascular disease given the paucity of data in such 
patients. The same is true for LABAs in patients with a 
reactive airway component and ICSs in patients at high risk 
for pneumonia.
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